Mark Breidenbach is an Executive Director and Senior Analyst with Oppenheimer & Co. covering emerging biotechnology. Previously Mark was at Roth Capital Partners as a lead Analyst covering Biotechnology and prior to that was a Managing Director and Senior Biotechnology Analyst at H.C. Wainwright & Co.. Prior to his Wall Street career, Mark was a Locum Scientist at Nature Publishing Group, and an Associate Specialist in Glycoproteomics and Metabolic Engineering at the Department of Chemistry, University of California Berkeley. Mark holds a Ph.D. in Molecular and Cellular Physiology from Stanford University, a M. Phil. from the Department of Molecular Biophysics and Biochemistry at Yale University, and a dual B.A. in Biology and Chemistry from Cornell University.